Cirena, Inc.
- Company typePrivate
- Founded2024
- HeadquartersBoulder, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Cirena, Inc. firmographics
Firmographics- Name
- Cirena, Inc.
- Legal name
- Cirena, Inc.
- Website
- https://cirena.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Cirena, Inc. industry classification
Industry- Product category
- Custom RNA Synthesis Services
- NAICS
- Chemical Manufacturing (325)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)
Keywords
Where Cirena, Inc. is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cirena, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Custom RNA Oligo Synthesis: One-time transaction-based ordering of custom long RNA oligos (100-300nt) with various modifications. Customers provide sequence, quantity, and modification specifications. Pricing varies by length, quantity, and complexity. Free feasibility checks offered; paid synthesis for approved sequences.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based custom synthesis |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Cirena, Inc. product offering
Product offeringCore offering
Cirena provides custom solid-phase chemical synthesis of long, high-purity RNA oligonucleotides (100–300 nucleotides) for research and therapeutic applications. Orders are purified by liquid chromatography, verified by mass spectrometry, and shipped with QC data; production scales from microgram to gram quantities with a pathway to GMP manufacturing via CDMO partners.
Product overview
Cirena is a biotechnology company offering custom long RNA synthesis as a single unified service. Their core offering combines proprietary Long RNA Synthesis Technology (using 2′-O-Thionocarbamate nucleoside phosphoramidites capable of producing 100-300 nt RNA) with customizable RNA Modifications that include their proprietary PACE Modification backbone chemistry. All products undergo LC purification and MS verification. The company offers scalable production from microgram to gram scales with a pathway to GMP manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- Custom RNA Oligo Synthesis Custom RNA oligo synthesis service delivering 100–300 nt oligonucleotides with site-specific chemical modifications, LC purification, and MS sequence-identity verification, ordered by sequence, quantity, and modification specifications and targeted at gene editing, RNA therapeutics, and structural biology researchers.
- PACE Backbone Modification A proprietary backbone chemistry option providing 1–2 orders of magnitude higher nuclease resistance than standard phosphorothioate modifications while preserving native-like duplex behavior, available on customer-requested oligos for gene editing and therapeutic RNA applications.
Quantifiable outcome
- 1-2 orders of magnitude higher intracellular stability vs. MS-modified counterparts over 24-96 hours
- +5 more outcomes
Companies that use Cirena, Inc.
Customer profileSegments4 records
Ideal customer profiles3 records
Cirena, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cirena, Inc. partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CDMOs (Contract Development and Manufacturing Organizations)supportiveCirena maintains close relationships with leading CDMOs (contract development and manufacturing organizations) to enable seamless scale-up to larger production volumes. The pathway to GMP manufacturing is described as straightforward through these partnerships.
Scale indicators3 records
Recent moves1 record
Expansion highlights4 records
Cirena, Inc. competitors and assessment
Company assessmentDirect peers
- Integrated DNA Technologies (IDT): IDT is the largest independent custom oligonucleotide synthesis provider, offering extensive RNA oligo capabilities with broad modification catalogues. It is the most directly comparable competitor to Cirena in custom RNA synthesis, but at much greater scale and with a more generalist positioning across all oligo lengths.
- TriLink BioTechnologies: TriLink specializes in mRNA synthesis and modified nucleotides, with overlapping capabilities in custom RNA and modified oligos for therapeutic and research use. It is a direct peer in the chemically modified RNA space, particularly for therapeutic-grade production.
- Aldevron: Aldevron (now part of Danaher) manufactures nucleic acids including mRNA, plasmid DNA, and recombinant proteins for therapeutic developers. It is a direct peer in nucleic acid manufacturing, particularly relevant as Cirena's customers scale from research to clinical-grade production.
- Eurofins Genomics: Eurofins Genomics offers custom oligonucleotide synthesis with broad modification menus at industrial scale. It competes directly with Cirena on standard and modified RNA oligos for research customers.
- GenScript: GenScript provides custom oligo and gene synthesis services with global operations and a wide modification catalogue. It is a direct peer to Cirena in custom RNA for research and therapeutic applications, particularly for Asian and US biotech customers.
- LGC Biosearch Technologies: LGC Biosearch is a custom oligo synthesis provider with deep catalog of modifications and probe chemistry. It competes directly with Cirena in custom RNA for genomics, gene editing, and modified oligo workflows.
Emerging players
- Twist Bioscience: Twist applies silicon-based DNA synthesis to large-scale oligo pools and gene fragments. While its core is DNA, it represents an emerging platform approach to nucleic acid synthesis that could eventually compete with chemical synthesis providers like Cirena in adjacent applications.
Broad incumbents
- Merck KGaA / Sigma-Aldrich (Custom Oligos): Sigma-Aldrich / Merck offers custom oligonucleotide synthesis services and a deep catalogue of nucleic acid chemistry products. It competes broadly with Cirena in custom modified oligos for academic and industrial research.
- Thermo Fisher Scientific (GeneArt / Oligo / Custom RNA): Thermo Fisher's GeneArt and related custom RNA offerings serve gene synthesis, mRNA, and modified oligos through its life-sciences tools portfolio. It is a broad incumbent that overlaps Cirena's custom synthesis capabilities as part of a much larger instrumentation and reagents franchise.
- Agilent Technologies (Custom Oligos): Agilent offers custom oligonucleotide synthesis and a broad life-sciences analytical portfolio. It competes in the modified oligo and nucleic acid chemistry space as part of a wider analytical instruments and reagents business.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Cirena, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cirena, Inc. leadership team
Management profileNumber of profiles
Profiles6 records
Cirena, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cirena, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cirena, Inc.
What does Cirena, Inc. do?
Cirena provides custom solid-phase chemical synthesis of long, high-purity RNA oligonucleotides (100–300 nucleotides) for research and therapeutic applications. Orders are purified by liquid chromatography, verified by mass spectrometry, and shipped with QC data; production scales from microgram to gram quantities with a pathway to GMP manufacturing via CDMO partners.
Is Cirena, Inc. a public or private company?
Cirena, Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cirena, Inc. founded?
Cirena, Inc. was founded in 2024. It employs 1 to 10 people.
Where is Cirena, Inc. based?
Cirena, Inc. is headquartered in Boulder, United States, in the North America region.
How does Cirena, Inc. make money?
One revenue line is on record: custom RNA Oligo Synthesis.
Who are Cirena, Inc.'s main competitors?
Direct peers on record are Integrated DNA Technologies (IDT), TriLink BioTechnologies, Aldevron, Eurofins Genomics, GenScript and LGC Biosearch Technologies. Twist Bioscience is listed as an emerging player. Broad incumbents are Merck KGaA / Sigma-Aldrich (Custom Oligos), Thermo Fisher Scientific (GeneArt / Oligo / Custom RNA) and Agilent Technologies (Custom Oligos).
Does Cirena, Inc. have an API?
No public API is recorded for Cirena, Inc..
What industry is Cirena, Inc. in?
Cirena, Inc.'s product category is Custom RNA Synthesis Services. Its primary akta.pro industry code is HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC). Its NAICS code is 325 and its SIC code is 2836.